Buy Recommendation, page-18

They changed their mind :

Column 1

0

Equity Story are very excited to add RESApp Health Limited (RAP) as a new Ten bagger. We are very excited where this company could go.They are simply developing an App that can diagnose respiratory illnesses . The Apps aim is to diagnose Acute conditions URTIs, influenza, bronchi)s, bronchioli)s, pneumonia, pertussis, croup Chronic Conditions Asthma, COPD, cystic fibrosis, bronchiectasis To understand the potential revenue model there are 125M doctor visits1 in the US for respiratory disease (10% of all visits) 6-8M doctor visits2 in Australia for respiratory disease Est. 700M+ doctor visits globally3 for respiratory disease High prevalence and growth in Asia . ResApp directly addresses the most common disease encountered by telehealth providers 1. 30% of telehealth consults for acute respiratory disease 2. 22.5M telehealth consults per year today for acute respiratory disease 3. Number of telehealth consultants growing at 56% per year 4. 700M+ global doctor visits each year for respiratory disease3 - Access through growth in telehealth plus in-person tests (in-clinic, in-hospital) There are two main sections to the development pediatric tests which resulted in >95% accuracy for pneumonia, asthma, bronchioli's, croup and URTIclassification - 89-99% accuracy for differential diagnosis of the most common respiratory conditions in children - Successfully demonstrated that voluntary coughs can achieve high levels of accuracy Adult test which are currently underway.Initially, Equity Story was going to wait until the adult tests were passed however after speaking to management the fact the pediatric tests passed with such flying colors with children alone the App is potentially a huge revenue earner. Rap is exciting for many reasons it has the potential to be a huge story next year and already is arguably very undervalued due the fact that the results with children were exceptional and already has paved the way to millions of dollars in potential revenue. Buy under 0.089.